VARIAZIONE DELLA CARICA VIRALE HCV DURANTE IL TRATTAMENTO FARMACOLOGICO CON BOCEPREVIR. STUDIO CONDOTTO PRESSO L’U.O.C. MALATTIE INFETTIVE DEL P.O. SANT’ANTONIO ABATE DI TRAPANI

Research output: Contribution to journalMeeting Abstract

Abstract

[automatically translated] We define Hepatitis C as a chronic degenerative disease of the liver with onset predominantly asymptomatic, only a few patients are in fact aware of being infected by the onset of an acute episode (among other things not very frequent) characterized by the appearance of jaundice , pain in the right hip, malaise and fatigue, and dominant sign, a significant increase in transaminases. Symptoms may occur after two or three months of infection at the peak of transaminases and the emergence of HCV RNA circulating. The responsible causative agent is a single-stranded RNA viruses and including 6 genotypes called HCV, transmitted primarily by direct contact through infected blood. If the previous therapeutic approach provided for the administration of the immune system-stimulating agents such as feron-alfa alfa associated with ribavirin, new therapeutic frontiers have foreseen the introduction of two drugs that have direct action against HCV; Boceprevir and telaprevir. These "agents Antivirals Direct" (DAA), inhibiting the NS3 / 4A protease of the virus, blocking the viral replication cycle.
Original languageItalian
Pages (from-to)48-49
Number of pages2
JournalJOURNAL OF BIOLOGICAL RESEARCH
Publication statusPublished - 2015

Cite this